Marie Kuhne - Publications

TH-302 (evofosfamide) monotherapy exerts anticancer activity in Ewing's sarcoma cells under hypoxia.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 16, 2025

Dually Modified Cellulose as a Non-Viral Vector for the Delivery and Uptake of HDAC3 siRNA.

Journal: Pharmaceutics

Published: October 25, 2023

HDACi Delivery Systems Based on Cellulose Valproate Nanoparticles.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: October 18, 2022

Analysis of HDACi-Coupled Nanoparticles: Opportunities and Challenges.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: October 18, 2022

Biocompatible valproic acid-coupled nanoparticles attenuate lipopolysaccharide-induced inflammation.

Journal: International journal of pharmaceutics

Published: January 05, 2021

Biocompatible sulfated valproic acid-coupled polysaccharide-based nanocarriers with HDAC inhibitory activity.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: May 13, 2020

Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing's sarcoma cells.

Journal: Journal of cancer research and clinical oncology

Published: March 20, 2020

Polysaccharide Nanoparticles Bearing HDAC Inhibitor as Nontoxic Nanocarrier for Drug Delivery.

Journal: Macromolecular bioscience

Published: February 06, 2020

Assessment of HDACi-Induced Cytotoxicity.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: October 21, 2016